Cabozantinib Evaluated in Aggressive Endometrial Cancer Subtype

Share this content:
Cabozantinib may have activity in carcinosarcoma and warrants further investigation.
Cabozantinib may have activity in carcinosarcoma and warrants further investigation.
The following article features coverage from the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. Click here to read more of Cancer Therapy Advisor's conference coverage.

Cabozantinib may have activity in carcinosarcoma and warrants further investigation, according to a study that will be presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.1

Carcinosarcoma is a rare and particularly aggressive subtype of endometrial cancer for which limited treatment options exist. Patients with carcinosarcoma have a median progression-free survival (PFS) of less than 2 months, with a 6-month PFS rate of less than 20%.

This multicenter, single-arm, phase 2 trial evaluated cabozantinib among patients with endometrial cancer, including a cohort of patients with carcinosarcoma (19 patients) and other subtypes. Patients were eligible if they had progressed within 1 year adjuvant chemotherapy or after first-line chemotherapy for metastatic disease. Further investigation was deemed warranted if 4 out of 10 patients demonstrated a response.

The median age at baseline was 66, and prior treatment included platinum-based chemotherapy and/or radiation. There were 15 patients evaluable for response in the carcinosarcoma cohort.

The median PFS was 3 months (95% CI, 2.7-4.6 months) with a 12-week PFS of 53% and estimated 6-month PFS of 13% (95% CI, 2-33%).

The most common adverse events with cabozantinib were fatigue and gastrointestinal upset. The most common grade 3 or worse events included hypertension, anemia, and diarrhea. Gastrointestinal fistula or perforation each occurred in 2 patients.

RELATED: Do Specialized Cancer Centers Improve Outcomes for Patients With Ewing Sarcoma?

The investigators indicated that the predefined endpoint for further study was met for the carcinosarcoma subtype.

Read more of Cancer Therapy Advisor's coverage of the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting by visiting the conference page.

Reference

  1. Mandilaras V, Dhani NC, Tan Q, et al. Exploratory phase II evaluation of cabozantinib in recurrent/metastatic uterine carcinosarcoma (CS): a study of the Princess Margaret, Chicago, and California phase II consortia. J Clin Oncol. 2017;35(suppl; abstr 5587).

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs